HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on 4D Molecular Therapeutics (NASDAQ:FDMT) and maintained a price target of $36.
August 10, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
4D Molecular Therapeutics (NASDAQ:FDMT) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $36.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for the stock. The maintenance of the $36 price target indicates that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100